Company intelligence / Profile preview

Cell-Easy

Toulouse, France

Ownership: Private
Development stage: Other

Overview

Cell-Easy specializes in developing and providing GMP-grade allogeneic and autologous cell therapy products (e.g. mesenchymal stem cells, T cells, NK cells). The company was first authorized in France to manufacture stem cells at industrial scale and supports partners with development from preclinical to clinical manufacturing. A first clinical trial is underway for Alzheimer's disease; most client work is in earlier/preclinical phases.

Therapeutic areas: OncologyNeurologyOtherImmunology
Modalities: Cell therapyCAR-T cell therapyNK cell therapyStem cell therapyInduced pluripotent stem cell derived therapyGene-modified cell therapy
Industry: Biotech

Drug pipeline

2 assets

CellReady

1 more asset in the full pipeline.

Request access →

Partnerships

University Hospital Centre (CHU) Toulouse

Beyond the preview

Go deeper on Cell-Easy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell-Easy.

Explore the full profile